WO2013167703A1 - Process for the manufacture of cyclic undecapeptides - Google Patents
Process for the manufacture of cyclic undecapeptides Download PDFInfo
- Publication number
- WO2013167703A1 WO2013167703A1 PCT/EP2013/059672 EP2013059672W WO2013167703A1 WO 2013167703 A1 WO2013167703 A1 WO 2013167703A1 EP 2013059672 W EP2013059672 W EP 2013059672W WO 2013167703 A1 WO2013167703 A1 WO 2013167703A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cyclosporin
- methyl
- compound
- formula
- ethyl
- Prior art date
Links
- UDPXHBLJKNDZLR-JZTHFVINSA-N CC(C)CC[C@@H](C(N(C)CC(N(C)C(C[C@@H](C/C=C/C)C[C@@H]1[N]2(CC(N(C)CC(OC)=O)=O)C1)C2=O)=O)=O)N(C)C([C@H](CC(C)C)N(C)C([C@@H](C)NC([C@H](C)NC([C@H](CC(C)C)N(C)C([C@H](C(C)C)NC([C@H](CC(C)C)NC)=O)=O)=O)=O)=O)=O Chemical compound CC(C)CC[C@@H](C(N(C)CC(N(C)C(C[C@@H](C/C=C/C)C[C@@H]1[N]2(CC(N(C)CC(OC)=O)=O)C1)C2=O)=O)=O)N(C)C([C@H](CC(C)C)N(C)C([C@@H](C)NC([C@H](C)NC([C@H](CC(C)C)N(C)C([C@H](C(C)C)NC([C@H](CC(C)C)NC)=O)=O)=O)=O)=O)=O UDPXHBLJKNDZLR-JZTHFVINSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/12—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by hydrolysis, i.e. solvolysis in general
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
- C07K7/645—Cyclosporins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the invention relates to novel process(es), novel process step(s) and novel intermediate(s) useful for the opening of Cyclosporin derivatives and subsequently for the preparation of cyclic polypeptides, more specifically, cyclic undecapeptides, such as alisporivir (also known as DEB025, Debio025, or Debio).
- cyclic undecapeptides such as alisporivir (also known as DEB025, Debio025, or Debio).
- the present invention relates to processes for the preparation of cyclic polypeptides, such as, for example, cyclic undecapeptides, such as alisporivir.
- Alisporivir is a cyclophilin (Cyp) inhibitor used for the treatment of hepatitis C virus (HCV) infection or HCV induced disorders as described in WO 2006/038088. Furthermore,
- WO2009/042892 describes methods for the use of alisporivir in the treatment of multiple sclerosis
- WO2009/098577 describes methods for the use of alisporivir in the treatment of muscular dystrophy
- WO2008/084368 describes methods for the use of alisporivir in the treatment of Ullrich congenital muscular dystrophy.
- Alisporivir and a synthesis thereof are described in WO 00/01715. Alisporivir has been attributed the CAS Registry Number 254435-95-5.
- AXX1 MeBmt, Bmt, MeLeu, Desoxy-MeBmt, Methylaminooctanoic acid
- AXX2 Abu, Ala, Thr, Val, Nva
- AXX10 MeLeu, Leu
- AXX1 1 MeVal, Val, D-MeVal
- Cyclic undecapeptides may be obtained bystrain selection, however obtaining most un-natural derivatives requires a chemical transformation which relies on opening of the cyclic polypeptide, for example, of Formula (la) or of Formula (lb) and subsequent amino acid replacement.
- cyclic polypeptide for example of Formula (la) are opened in a highly selective process and an amino acid residue is removed via the Edman degradation to access the opened cyclic polypeptide as a key intermediate (Wenger, R. M. In Peptides 1996; Ramage, R.; Epton, R., Eds.; The European Peptides Society, 1996; pp. 173; Wenger, R. M. et al. Tetrahedron Letters 2000, 41, 7193.). Numerous scientists and companies have used this reliable and selective strategy wherein pure cyclosporin A and purification by column chromatography have been used to obtain cyclic undecapeptides.
- purification of products involve several steps of purification by liquid chromatography on silica. Beside the moderate overall obtained yield, the major drawback of this purification scheme is the very high costs for the chromatography steps.
- Large-scale purification processes of such products derived from cyclosporin A or its structural analogues described in the literature generally involve a chromatographic purification or at least a pre-purification by adsorption chromatography. Such pre-purification may be followed, for instance, by extraction, counterflow extraction, and/or supercritical fluid extraction.
- pre-purification may be followed, for instance, by extraction, counterflow extraction, and/or supercritical fluid extraction.
- none of these techniques appear to be fully satisfactory for obtaining the key opened intermediates with the desired quality requirements, with an acceptable overall yield, and at an acceptable cost for an industrial scale production, as costly precursors of high quality were required.
- dimethoxycarbenium ions (described in Novartis patent application EP 0 908 461 A1 for the methylation of Cephalosporine derivatives), do the same chemistry as oxonium ions (trimethyl or triethyloxonium Meerwein salts) in the opening of the macrocyclic polypeptide.
- the new conditions can advantageously be prepared in situ, thus avoiding the handling of hazardous and hygroscopic substance, can proceed in a variety of solvents such as for example toluene, xylene, anisole, by-passing the need for using the undesirable chlorinated solvents such as dichloromethane or dichloroethane, and avoid the use of oxonium Meerwein salts originating from the genotoxic epichlorhydrin.
- Either the dedicated carbenium tetrafluoroborate salt or the in situ generated reactive species made by the reaction of boron trifluoride and an orthoester derivative, preferably trimethyl orthoformate, will result in the desired opened polypeptides such as compound 3 below.
- undecapeptides such as alisporivir.
- the process according to the present disclosure may also be applied to other cyclosporins that can be opened via the same sequence. It was found that opened cyclosporin salts, such as hydrochloric acid (HCI), fluoroboric acid (HBF 4) , or hexafluorophosphoric acid (HPF 6 ), can be formed at several stages.
- HCI hydrochloric acid
- HHF 4 fluoroboric acid
- HPF 6 hexafluorophosphoric acid
- the present invention provides novel crystalline intermediates, such as cylosporine esters, such as acetate, pivaloate, and opened cyclosporin A, cyclosporin B, cyclosporin D or cyclosporin G salts such as the HCI salt, the HBF 4 salt, or the HPF 6 salt, and processes to generate them.
- novel crystalline intermediates such as cylosporine esters, such as acetate, pivaloate, and opened cyclosporin A, cyclosporin B, cyclosporin D or cyclosporin G salts such as the HCI salt, the HBF 4 salt, or the HPF 6 salt
- the method includes the steps of acylation of cyclosporin A, to form acetyl-Cyclosporin A; ring opening of the acetyl- Cyclosporin A; and crystallizing the ring opened acetyl-Cyclosporin A to obtain the compound of formula 3.
- R is methyl, ethyl, propyl or phenyl and R' is methyl or ethyl.
- the method includes the steps of Edman degradation of compound of formula 3; and then crystallizing the compound to obtain the compound of formula 4.
- a process for preparing a compound of formula 4 or a salt thereof is provided,
- the method includes the steps of: acylation of cyclosporin A to form acetyl-Cyclosporin A; ring opening of the acetyl- Cyclosporin A; and crystallizing the ring opened acetyl-Cyclosporin A to obtain the compound of formula 3
- R is methyl, ethyl, propyl or phenyl and R' is methyl or ethyl.
- R is methyl, ethyl, propyl or phenyl and R' is methyl or ethyl.
- Figure 1 is a proton NMR spectra for compound 3.
- Figure 2 is a proton NMR spectra for compound 4.
- R 2 is:
- alisporivir can be made by converting cyclosporin A (compound (1) wherein R 2 is ethyl) into a compound of formula 4 as shown above by acylation of cyclosporin A, to form acetyl-Cyclosporin A (2); ring opening; crystallization to obtain a compound 3, Edman degradation of compound 3; crystallization to obtain a compound 4 and then cyclizing compound 4 to form alisporivir (as shown below).
- the invention specially relates to the processes described in each section.
- the invention likewise relates, independently, to every single step described in a process sequence within the corresponding section. Therefore, each and every single step of any process, consisting of a sequence of steps, described herein is itself a preferred embodiment of the present invention.
- the invention also relates to those embodiments of the process, according to which a compound obtainable as an intermediate in any step of the process is used as a starting material.
- the invention also relates to intermediates which have been specifically developed for the preparation of the compounds according to the invention, to their use and to processes for their preparation. It is noted that in the present application, explanations made in one section may also be applicable for other sections, unless otherwise stated.
- Cyclosporin A, cyclosporin B, cyclosporin D or cyclosporin G or salts thereof, may be prepared, for example by fermentation.
- the present invention relates to a method for preparing compound of formula 3, comprising the steps of acylation of cyclosporin A, cyclosporin B, cyclosporin D or cyclosporin G to form acetyl-Cyclosporin A, B, D, or G; ring opening; and crystallization.
- the present invention relates to a method for preparing compound of formula 4 or a salt thereof, comprising Edman degradation, a reaction well known in the art, of a compound of formula 3 and crystallization thereof to obtain compound of formula 4.
- Another embodiment of the present invention relates to a method for preparing a compound of formula 3 or formula 4 wherein the purity of the Cyclosporin A starting material is >80% by weight
- Another embodiment of the present invention relates to a method for preparing a compound of formula 3 or formula 4 wherein the purity of the Cyclosporin A starting material is >85% by weight.
- Another embodiment of the present invention relates to a method for preparing a compound of formula 3 or formula 4 wherein the purity of the Cyclosporin A starting material is 60 to 80%, weight % assay.
- R is methyl, ethyl, propyl or phenyl
- R' is methyl or ethyl
- R 2 is methyl, ethyl, or propyl
- R is methyl, ethyl, propyl or phenyl
- R' is methyl or ethyl
- R 2 is methyl, ethyl, or propyl
- R is methyl, ethyl, propyl or phenyl and R' is methyl or ethyl.
- Acetyl-Cyclosporin A (100g as is) was reacted with trimethyloxonium tetrafluoroborate (32 g) at 20-25*0 in dichloromethane (180 mL). After 20 h, acetonitrile (200 mL) and water (650 mL) were added to perform the hydrolysis. After 3 h, at 20-25°C, the phases were separated and the reaction mixture was dried by azeotropic distillation with 2-Methy!-Tetrahydrofuran (solvent exchange dichloromethane 1 2-Methyl-Tetrahydrofuran).
- the "undecapeptide amino acid" precursor (5 to 13% to the overall end mass) dissolved in dichloromethane and the DCC dissolved into dichloromethane were added continuously in parallel in ca. 10 h to a mixture of CI-HOBT, and NMM in dichloromethane at 40 °C. At the end of the addition, the mixture was stirred for an additional 2h, filtered to remove the DCU salt and concentrated to give Alisporivir as a crude product.
Abstract
Description
Claims
Priority Applications (19)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020147031112A KR20150006435A (en) | 2012-05-09 | 2013-05-08 | Process for the manufacture of cyclic undecapeptides |
CA2868940A CA2868940A1 (en) | 2012-05-09 | 2013-05-08 | Process for the manufacture of cyclic undecapeptides |
SG11201406303XA SG11201406303XA (en) | 2012-05-09 | 2013-05-08 | Process for the manufacture of cyclic undecapeptides |
MX2014013613A MX2014013613A (en) | 2012-05-09 | 2013-05-08 | Process for the manufacture of cyclic undecapeptides. |
US14/399,261 US20150087808A1 (en) | 2012-05-09 | 2013-05-08 | Process for the manufacture of cyclic undecapeptides |
IN8483DEN2014 IN2014DN08483A (en) | 2012-05-09 | 2013-05-08 | |
JP2015510823A JP2015517481A (en) | 2012-05-09 | 2013-05-08 | Method for producing cyclic undecapeptide |
CN201380023760.8A CN104284902A (en) | 2012-05-09 | 2013-05-08 | Process for the manufacture of cyclic undecapeptides |
BR112014027648A BR112014027648A2 (en) | 2012-05-09 | 2013-05-08 | process for production of cyclic undecapeptides |
AU2013257989A AU2013257989A1 (en) | 2012-05-09 | 2013-05-08 | Process for the manufacture of cyclic undecapeptides |
EP13722740.1A EP2847211A1 (en) | 2012-05-09 | 2013-05-08 | Process for the manufacture of cyclic undecapeptides |
EA201492036A EA024903B1 (en) | 2012-05-09 | 2013-05-08 | Process for the manufacture of cyclic undecapeptides |
MA37498A MA20150231A1 (en) | 2012-05-09 | 2013-05-08 | Process for producing cyclic undecapeptides |
TNP2014000411A TN2014000411A1 (en) | 2012-05-09 | 2014-09-30 | Process for the manufacture of cyclic undecapeptides |
IL235428A IL235428A0 (en) | 2012-05-09 | 2014-10-30 | Process for the manufacture of cyclic undecapeptides |
PH12014502499A PH12014502499A1 (en) | 2012-05-09 | 2014-11-10 | Process for the manufacture of cyclic undecapeptides |
HK15102858.0A HK1202555A1 (en) | 2012-05-09 | 2015-03-20 | Process for the manufacture of cyclic undecapeptides |
US15/198,152 US9840534B2 (en) | 2012-05-09 | 2016-06-30 | Process for the manufacture of cyclic undecapeptides |
AU2016222370A AU2016222370B2 (en) | 2012-05-09 | 2016-08-31 | Process for the manufacture of cyclic undecapeptides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261644616P | 2012-05-09 | 2012-05-09 | |
US61/644,616 | 2012-05-09 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/399,261 A-371-Of-International US20150087808A1 (en) | 2012-05-09 | 2013-05-08 | Process for the manufacture of cyclic undecapeptides |
US15/198,152 Continuation US9840534B2 (en) | 2012-05-09 | 2016-06-30 | Process for the manufacture of cyclic undecapeptides |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2013167703A1 true WO2013167703A1 (en) | 2013-11-14 |
WO2013167703A9 WO2013167703A9 (en) | 2014-11-20 |
Family
ID=48444372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2013/059672 WO2013167703A1 (en) | 2012-05-09 | 2013-05-08 | Process for the manufacture of cyclic undecapeptides |
Country Status (24)
Country | Link |
---|---|
US (2) | US20150087808A1 (en) |
EP (1) | EP2847211A1 (en) |
JP (3) | JP2015517481A (en) |
KR (1) | KR20150006435A (en) |
CN (2) | CN104284902A (en) |
AR (1) | AR090964A1 (en) |
AU (2) | AU2013257989A1 (en) |
BR (1) | BR112014027648A2 (en) |
CA (1) | CA2868940A1 (en) |
CL (1) | CL2014003014A1 (en) |
CO (1) | CO7141428A2 (en) |
EA (1) | EA024903B1 (en) |
EC (1) | ECSP14030537A (en) |
HK (1) | HK1202555A1 (en) |
IL (1) | IL235428A0 (en) |
IN (1) | IN2014DN08483A (en) |
MA (1) | MA20150231A1 (en) |
MX (1) | MX2014013613A (en) |
PE (1) | PE20142433A1 (en) |
PH (1) | PH12014502499A1 (en) |
SG (1) | SG11201406303XA (en) |
TN (1) | TN2014000411A1 (en) |
TW (1) | TW201350508A (en) |
WO (1) | WO2013167703A1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105693820A (en) * | 2014-11-27 | 2016-06-22 | 武汉药明康德新药开发有限公司 | Degradation method of cyclosporine A |
WO2018207904A1 (en) | 2017-05-12 | 2018-11-15 | 中外製薬株式会社 | Method for producing cyclic organic compound |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0908461A1 (en) | 1993-10-22 | 1999-04-14 | BIOCHEMIE Gesellschaft m.b.H. | Process for the production of cephalosporins |
WO2000001715A1 (en) | 1998-07-01 | 2000-01-13 | Debiopharm S.A. | Novel cyclosporin with improved activity profile |
WO2000046239A1 (en) * | 1999-02-05 | 2000-08-10 | Debiopharm S.A. | Cyclosporin derivatives and method for the production of said derivatives |
WO2006038088A1 (en) | 2004-10-01 | 2006-04-13 | Debiopharm Sa | Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin |
WO2008084368A2 (en) | 2007-01-04 | 2008-07-17 | Debiopharm Sa | Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy |
WO2009042892A1 (en) | 2007-09-26 | 2009-04-02 | Oregon Health & Science University | Cyclic undecapeptides and derivatives as multiple sclerosis therapies |
WO2009098577A2 (en) | 2008-02-08 | 2009-08-13 | Debiopharm Sa | Non-immunosuppressive cyclosporin for the treatment of muscular dystrophy |
WO2010052559A1 (en) | 2008-11-06 | 2010-05-14 | Debio Recherche Pharmaceutique S.A. | Cycloundecadepsipeptide compounds and use of said compounds as a medicament |
WO2010088573A1 (en) * | 2009-01-30 | 2010-08-05 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues for preventing or treating hepatitis c infection |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60208180T2 (en) * | 2001-04-20 | 2006-08-17 | Debiopharm S.A. | MODIFIED CYCLOSPORIN APPLICABLE AS MEDICAMENT PREPARATION AND USE THEREOF |
IL160763A0 (en) * | 2001-10-19 | 2004-08-31 | Isotechnika Inc | Synthesis of cyclosporin analog |
TW200505946A (en) | 2003-04-08 | 2005-02-16 | Hoffmann La Roche | Process for preparation of cyclosporin a analog |
EP1828229A4 (en) * | 2004-12-17 | 2010-06-30 | Isotechnika Inc | Metabolites of cyclosporin analogs |
US7910378B2 (en) * | 2007-12-14 | 2011-03-22 | Siemens Healthcare Diagnostics Inc. | Methods for detection of hydrophobic drugs |
US8536114B2 (en) * | 2008-12-31 | 2013-09-17 | Scynexis, Inc. | Macrocycles |
CN103153330B (en) * | 2010-08-12 | 2017-08-18 | 美国科技环球有限公司 | Application of the new cyclosporin derivative in the treatment and prevention of virus infection |
-
2013
- 2013-05-07 AR ARP130101557A patent/AR090964A1/en unknown
- 2013-05-08 AU AU2013257989A patent/AU2013257989A1/en not_active Abandoned
- 2013-05-08 CN CN201380023760.8A patent/CN104284902A/en active Pending
- 2013-05-08 MX MX2014013613A patent/MX2014013613A/en unknown
- 2013-05-08 SG SG11201406303XA patent/SG11201406303XA/en unknown
- 2013-05-08 KR KR1020147031112A patent/KR20150006435A/en not_active Application Discontinuation
- 2013-05-08 CA CA2868940A patent/CA2868940A1/en not_active Abandoned
- 2013-05-08 IN IN8483DEN2014 patent/IN2014DN08483A/en unknown
- 2013-05-08 EP EP13722740.1A patent/EP2847211A1/en not_active Withdrawn
- 2013-05-08 PE PE2014001983A patent/PE20142433A1/en not_active Application Discontinuation
- 2013-05-08 WO PCT/EP2013/059672 patent/WO2013167703A1/en active Application Filing
- 2013-05-08 CN CN201810575515.2A patent/CN108715606A/en active Pending
- 2013-05-08 EA EA201492036A patent/EA024903B1/en not_active IP Right Cessation
- 2013-05-08 MA MA37498A patent/MA20150231A1/en unknown
- 2013-05-08 TW TW102116414A patent/TW201350508A/en unknown
- 2013-05-08 JP JP2015510823A patent/JP2015517481A/en not_active Withdrawn
- 2013-05-08 BR BR112014027648A patent/BR112014027648A2/en not_active IP Right Cessation
- 2013-05-08 US US14/399,261 patent/US20150087808A1/en not_active Abandoned
-
2014
- 2014-09-30 TN TNP2014000411A patent/TN2014000411A1/en unknown
- 2014-10-30 IL IL235428A patent/IL235428A0/en unknown
- 2014-11-07 CL CL2014003014A patent/CL2014003014A1/en unknown
- 2014-11-10 PH PH12014502499A patent/PH12014502499A1/en unknown
- 2014-11-10 CO CO14248207A patent/CO7141428A2/en unknown
- 2014-12-08 EC ECIEPI201430537A patent/ECSP14030537A/en unknown
-
2015
- 2015-03-20 HK HK15102858.0A patent/HK1202555A1/en unknown
-
2016
- 2016-06-30 US US15/198,152 patent/US9840534B2/en not_active Expired - Fee Related
- 2016-08-31 AU AU2016222370A patent/AU2016222370B2/en not_active Ceased
-
2017
- 2017-08-29 JP JP2017164867A patent/JP2018035154A/en not_active Withdrawn
-
2019
- 2019-09-30 JP JP2019179311A patent/JP2020033349A/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0908461A1 (en) | 1993-10-22 | 1999-04-14 | BIOCHEMIE Gesellschaft m.b.H. | Process for the production of cephalosporins |
WO2000001715A1 (en) | 1998-07-01 | 2000-01-13 | Debiopharm S.A. | Novel cyclosporin with improved activity profile |
WO2000046239A1 (en) * | 1999-02-05 | 2000-08-10 | Debiopharm S.A. | Cyclosporin derivatives and method for the production of said derivatives |
WO2006038088A1 (en) | 2004-10-01 | 2006-04-13 | Debiopharm Sa | Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin |
WO2008084368A2 (en) | 2007-01-04 | 2008-07-17 | Debiopharm Sa | Non-immunosuppressive cyclosporin for treatment of ullrich congenital muscular dystrophy |
WO2009042892A1 (en) | 2007-09-26 | 2009-04-02 | Oregon Health & Science University | Cyclic undecapeptides and derivatives as multiple sclerosis therapies |
WO2009098577A2 (en) | 2008-02-08 | 2009-08-13 | Debiopharm Sa | Non-immunosuppressive cyclosporin for the treatment of muscular dystrophy |
WO2010052559A1 (en) | 2008-11-06 | 2010-05-14 | Debio Recherche Pharmaceutique S.A. | Cycloundecadepsipeptide compounds and use of said compounds as a medicament |
WO2010088573A1 (en) * | 2009-01-30 | 2010-08-05 | Enanta Pharmaceuticals, Inc. | Cyclosporin analogues for preventing or treating hepatitis c infection |
Non-Patent Citations (4)
Title |
---|
J.F. GUICHOUX: "De nouveaux analogues de Cycloposrine A comme agent anti-HIV-1", PHD THESIS, 2002 |
See also references of EP2847211A1 |
WENGER, R. M. ET AL., TETRAHEDRON LETTERS, vol. 41, 2000, pages 7193 |
WENGER, R. M.: "Peptides", 1996, THE EUROPEAN PEPTIDES SOCIETY, pages: 173 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105693820A (en) * | 2014-11-27 | 2016-06-22 | 武汉药明康德新药开发有限公司 | Degradation method of cyclosporine A |
WO2018207904A1 (en) | 2017-05-12 | 2018-11-15 | 中外製薬株式会社 | Method for producing cyclic organic compound |
KR20200007863A (en) | 2017-05-12 | 2020-01-22 | 추가이 세이야쿠 가부시키가이샤 | Method for producing cyclic organic compound |
US11807664B2 (en) | 2017-05-12 | 2023-11-07 | Chugai Seiyaku Kabushiki Kaisha | Method for producing cyclic organic compound |
Also Published As
Publication number | Publication date |
---|---|
IN2014DN08483A (en) | 2015-05-08 |
TW201350508A (en) | 2013-12-16 |
CL2014003014A1 (en) | 2015-03-06 |
KR20150006435A (en) | 2015-01-16 |
MX2014013613A (en) | 2015-02-12 |
ECSP14030537A (en) | 2015-09-30 |
EA201492036A1 (en) | 2015-02-27 |
AR090964A1 (en) | 2014-12-17 |
HK1202555A1 (en) | 2015-10-02 |
IL235428A0 (en) | 2014-12-31 |
US9840534B2 (en) | 2017-12-12 |
CN108715606A (en) | 2018-10-30 |
CN104284902A (en) | 2015-01-14 |
AU2013257989A1 (en) | 2014-10-23 |
JP2015517481A (en) | 2015-06-22 |
SG11201406303XA (en) | 2014-11-27 |
MA20150231A1 (en) | 2015-07-31 |
PE20142433A1 (en) | 2015-02-02 |
US20160304554A1 (en) | 2016-10-20 |
JP2018035154A (en) | 2018-03-08 |
JP2020033349A (en) | 2020-03-05 |
WO2013167703A9 (en) | 2014-11-20 |
EP2847211A1 (en) | 2015-03-18 |
AU2016222370A1 (en) | 2016-09-15 |
EA024903B1 (en) | 2016-10-31 |
TN2014000411A1 (en) | 2015-12-21 |
AU2016222370B2 (en) | 2017-10-05 |
PH12014502499A1 (en) | 2014-12-22 |
CA2868940A1 (en) | 2013-11-14 |
BR112014027648A2 (en) | 2017-06-27 |
US20150087808A1 (en) | 2015-03-26 |
CO7141428A2 (en) | 2014-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4477777B2 (en) | New cyclosporine | |
MXPA00013019A (en) | Novel cyclosporin with improved activity profile. | |
JP2009523713A (en) | Template-immobilized peptide mimetic | |
WO2008143996A1 (en) | New chemical processes | |
KR101330238B1 (en) | Template-fixed beta-hairpin peptidomimetics with cxcr4 antagonizing activity | |
WO2012016595A1 (en) | β-HAIRPIN PEPTIDOMIMETICS | |
JP2021038230A (en) | System and method for solution phase gap peptide synthesis | |
CN103476789A (en) | Processes for the manufacture of macrocyclic depsipeptides and new intermediates | |
JP2020033349A (en) | Process for manufacturing cyclic undecapeptides | |
EP3160985B1 (en) | Process for the production of d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide | |
CN100584859C (en) | Process for the preparation of echinocandin derivatives | |
CN107474107A (en) | GLYX 13 preparation method and the compound for preparing GLYX 13 | |
WO2015197723A1 (en) | Process for preparing d-arginyl-2,6-dimethyl-l-tyrosyl-l-lysyl-l-phenylalaninamide | |
Altherr et al. | The ‘Azirine/Oxazolone Method’in Peptaibol Synthesis: Preparation of a Derivative of Trichotoxin A‐50 (G) | |
JP6638016B2 (en) | Cyclopeptide, pharmaceutical or cosmetic composition containing the same, and method for producing the same | |
Hu et al. | Cyclosporin analogs modified in the 3, 7, 8-positions: substituent effects on peptidylprolyl isomerase inhibition and immunosuppressive activity are nonadditive | |
CN112876502B (en) | Preparation method of N-trimethylsiloxyethoxycarbonyl-N-methyl-L/D-leucine | |
WO2005034982A1 (en) | Cyclic peptide antitumor agents | |
Tuchscherer et al. | Peptidomimetics for Bridging Structure and Function: Pseudo-Prolines (ΨPro) in Peptide Synthesis, Molecular Recognition, and Drug Design | |
CN105859723A (en) | Proline containing cyclo-dipeptide and synthesis method thereof | |
BG65033B1 (en) | Echinocandin derivatives, preparation method and application thereof as anti-fungal agents | |
HUE034308T2 (en) | Synthesis of hydantoin containing peptide products | |
CN107827956B (en) | Synthesis method of active cyclic octapeptide reniohalistatin E and analogues thereof | |
CN117567566A (en) | Liquid phase synthesis process of cyclohexapeptide-9 | |
CN109912696A (en) | A kind of liquid-phase synthesis process of cyclosporin A and the like |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 13722740 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2868940 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2013257989 Country of ref document: AU Date of ref document: 20130508 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: IDP00201406690 Country of ref document: ID |
|
ENP | Entry into the national phase |
Ref document number: 20147031112 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 001983-2014 Country of ref document: PE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14399261 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2015510823 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/013613 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14248207 Country of ref document: CO Ref document number: 2013722740 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: A201410510 Country of ref document: UA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 201492036 Country of ref document: EA |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014027648 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014027648 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141105 |